In a groundbreaking achievement, Sefako Makgatho Health Sciences University (SMU) Master’s student Nondumiso Nkosi has developed a pioneering diagnostic assay for Hepatitis B, addressing a critical need in regions where the disease is endemic. This innovation has earned her recognition as a rising star in the intellectual property (IP) landscape.
Nkosi’s journey into innovation and entrepreneurship began with her attendance at the Bio Africa Convention in 2023, where her project was selected for presentation and won the runner-up award. “This recognition was an eye-opener, making me realise the magnitude and potential impact of my work,” she reflects.
Her diagnostic assay aims to bridge the gap in accessible and efficient Hepatitis B diagnosis, particularly in resource-limited settings. “Current diagnostic methods are often inaccessible or inadequate, making early detection and effective management difficult,” Nkosi explains. My innovation provides a more accessible and efficient solution tailored to the African healthcare landscape.
The collaboration with the Department of Clinical Laboratory Medicine at Nagoya City University Hospital in Japan served as a foundational base for the innovation. “This partnership enabled the development of a diagnostic tool tailored to the unique healthcare challenges in Africa,” Nkosi notes.
With the unwavering support of her supervisor, Dr Omphile Simani, Nkosi’s innovation holds significant potential for the early detection and management of Hepatitis, contributing substantially to public health solutions. “Dr Simani saw the potential in my vision and encouraged me every step of the way,” Nkosi acknowledges.
The SMU Technology Transfer Office (TTO) has been instrumental in supporting Nkosi’s innovation, providing guidance on intellectual property protection and commercialisation. “We are working with Nkosi and Simani to identify potential industry partners to commercialise the assay,” says Mohlatlego Sebola, who is responsible for establishing and operationalising the TTO.
Nkosi’s achievement is a testament to the university’s commitment to innovation and entrepreneurship. As SMU Acting Vice-Chancellor Professor Tandi Matsha-Erasmus notes: “Our commitment at SMU is clear: we nurture innovation, excellence, and community service. Nkosi’s innovation is a shining example of this commitment.”
The impact of Nkosi’s innovation extends beyond the academic realm. Hepatitis B is a major global health challenge, ranking as the seventh leading cause of death worldwide. Millions of people, particularly in Africa, suffer from chronic HBV infections, leading to severe liver disease, cirrhosis, and hepatocellular carcinoma.
Nkosi’s diagnostic assay has the potential to save countless lives by providing an accessible and efficient diagnostic solution. Her innovation serves as a beacon of hope for those affected by Hepatitis B, and her story is a testament to the power of dedication, innovation, and collaboration in driving positive change.
As Nkosi continues to break barriers in biomedical innovation, she remains committed to her vision of improving public health outcomes. Her pioneering diagnostic assay for Hepatitis B is a groundbreaking achievement that has the potential to revolutionise public health outcomes.
By Dimakatso Modise
